Patent Number: 
Section: claims

1. A method for the treatment of a Patient comprising administering to the Patient having bone pain, one or more calcific tumors, or in need of a bone marrow suppressing procedure, a pharmaceutically-acceptable formulation of a chelate composition comprising a Clinically Relevant Dosage of the composition that is therapeutically effective, said composition is administered to said Patient as either:i) the formulation having a chelate composition consisting essentially of Sm-153 and DOTMP or a physiologically-acceptable salt thereof, orii) the formulation as reconstituted from a kit containing as two separate components, the DOTMP chelant and the Sm-153 isotope, which components are mixed to form the chelate composition at the appropriate time prior to use,wherein the Sm-153 isotope possesses an extended Expiration Date of greater than or equal to about 5 days, and wherein the Sm-153 dosage is at least 35 mCi;with the proviso that the chelate composition is prepared by a process comprising the steps of:a) irradiating Sm-152 in a lower flux portion of the nuclear reactor having less than 8.5×1013 neutron/cm2-sec to form low specific activity Sm-153 , wherein the isotope composition after the irradiation contains mainly Sm-152 and Sm-153 with reduced trace impurity of Eu-154 less than 0.093 μCi Eu-154/mCi Sm-153 after 5 days of decay, thereby providing an extended Expiration Date greater than or equal to about 5 days;b) taking the prepared isotope mixture from step a) and either using it in step e) or allowing it to decay and then using it in step c) which decay further lowers the specific activity of the Sm-153 formed in step a) while maintaining less than 0.093 μCi of Eu-154 per mCi of Sm-153; andc) reacting DOTMP or a physiologically-acceptable salt thereof as the chelant with the Sm-153 isotope mixture from step b) in, an aqueous solvent to form the radioactive chelate composition that is pharmaceutically-acceptable and has a Clinically Relevant Dosage that is therapeutically effective. 2. The method of claim 1 wherein the dosage of Sm-153 is about 70 mCi or more. 3. The method of claim 1 wherein the Expiration Date is about 10 days or more. 4. The method of claim 1 wherein the formulation has a reduced radionudidic impurity profile, and a longer shelf life. 5. The method of claim 4 wherein the formulation has a reduced radionuclidic impurity profile which contains less than 0.093 μCi of Eu-154 per mCi of Sm-153 at Expiration Date. 6. The method of claim 1 wherein the Clinically Relevant Dosage is about 0.5 mCi per kg body weight or about 35 mCi for a 70 kg patient. 7. The method of claim 1 wherein the Clinically Relevant Dosage is about 1.0 mCi per kg body weight or about 70 mCi for a 70 kg patient. 8. The method of claim 1 wherein the pharmaceutically-acceptable formulation comprises one or more of an aqueous solvent, preservatives, diluents, excipients and buffers. 9. The method of claim 1 wherein the Patient has formulation injected intravenously. 10. A pharmaceutically-acceptable chelate composition comprising a Clinically Relevant Dosage of the composition that is therapeutically effective and pharmaceutically-acceptable, wherein Sm-153 isotope used in the said chelate composition possessing an extended Expiration Date of greater than or equal to about 5 days and said chelate consisting essentially of Sm-153 and DOTMP or a physiologically-acceptable salt thereof, wherein the Sm-153 dosage is at least 35 mCi;with the proviso that the chelate composition is prepared by a process comprising the steps of:a) irradiating Sm-152 in a lower flux portion of the nuclear reactor having less than 8.5+1013 neutron/cm2-sec to form low specific activity Sm-153, wherein the isotope composition after the irradiation contains mainly Sm-152 and Sm-153 with reduced trace impurity of Eu-154 less than 0.093 μCi Eu-154/mCi Sm-153 after 5 days of decay, thereby providing an extended Expiration Date greater than or equal to about 5 days;b) taking the, prepared isotope mixture from step a) and either using it in step c) or allowing it to decay and then using it in step c) which decay further lowers the specific activity of the Sm-153 formed in step a) while, maintaining less than 0.093 μCi of Eu-154 per mCi of Sm-153; andc) reacting DOTMP or a physiologically-acceptable salt thereof as the chelant with the Sm-153 isotope mixture from step b) in an aqueous solvent to form the radioactive chelate composition that is pharmaceutically-acceptable and has a Clinically Relevant Dosage that is therapeutically effective. 11. A pharmaceutical folinulation comprising a chelate composition comprising a Clinically Relevant Dosage of the composition that is therapeutically effective and pharmaceutically-acceptable, Sm-153 used in the said chelate composition possessing an extended Expiration Date of greater than or equal to about 5 days and said chelate consisting essentially of Sm-153 and DOTMP or a physiologically-acceptable salt thereof, wherein the Sm-153 dosage is at least 35 mCi, and a pharmaceutically-acceptable carrier;with the proviso that the chelate composition is prepared by a process comprising the steps of:a) irradiating Sm-152 in a lower flux portion of the nuclear reactor having less than 8.5+1013 neutron/cm2-sec to form low specific activity Sm-153, wherein the isotope composition after the irradiation contains mainly Sm-152 and Sm-153 with reduced trace impurity of Eu-154 less than 0.093 μCi Eu-154/mCi Sm-153 after 5 days of decay, thereby providing an extended Expiration Date greater than or equal to about 5 days;b) taking the prepared isotope mixture from step a) and either using, it in step c) or allowing it to decay and then using it in step c) which decay further lowers the specific activity of the Sm-153 formed in step a) while maintaining less, than 0.093 μCi of Eu-154 per mCi of Sm-153; andc) reacting DOTMP or a physiologically-acceptable salt thereof as the chelant with the Sm-153 isotope mixture from step b) in an aqueous solvent to form the radioactive chelate composition that is pharmaceutically-acceptable and has a Clinically Relevant Dosage that is therapeutically effective. 12. The formulation of claim 11 wherein a kit comprising two separate components, the DOTMP chelant and the Sm-153 isotope, are mixed to form the chelate at the appropriate time prior to use. 13. The formulation of claim 11 wherein the pharmaceutically-acceptable carrier comprises one or more of an aqueous solvent, preservatives, diluents, excipients and buffers. 14. The formulation of claim 12 wherein the pharmaceutically-acceptable carrier comprises one or more of an aqueous solvent, preservatives, diluents, excipients and buffers.